Neoleukin Therapeutics: Lead program NL-201: cytokine mimetic (neoleukin) to activate immune cells for cancer immunotherapy; first de novo protein therapeutic ever created. IND planned for 2020. Potential for best-in-class IL-2/IL-15.
Healthcare/Drug Manufacturers
Based in...
US - Pacific
Clinical Stage
Pre-Clinical Stage
Disease Space
Allergy, Autoimmune, Immuno-Oncology, Oncology
Public, USA
Market Cap
100MM - 500MM
1616 Eastlake Avenue E
Suit 360
Seattle, WA 98109
United States

Company Participants at Solebury Trout Virtual Management Access Event - 1x1 conference calls

  • Jonathan G. Drachman, CEO

Top 10 Holders of Neoleukin Therapeutics, Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Redmile Group LLC 14.36 4,041,211 46.92 13F 6/30/20
Ecor1 Capital LLC 12.57 3,536,684 41.06 13F 6/30/20
Baker Bros. Advisors LP 12.07 3,397,740 39.45 13F 6/30/20
Pictet Asset Management Ltd. 6.01 1,690,849 19.63 13F 6/30/20
Opaleye Management, Inc. 4.98 1,400,000 16.25 13F 6/30/20
Renaissance Technologies LLC 3.70 1,040,292 12.08 13F 6/30/20
BlackRock Fund Advisors 3.67 1,034,076 12.01 13F 6/30/20
Boxer Capital LLC 3.59 1,009,255 11.72 13F 6/30/20
The Vanguard Group, Inc. 3.56 1,006,812 11.69 Funds 8/31/20
BlackRock Institutional Trust Co. NA 3.33 937,105 10.88 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.